Portola Pharmaceuticals Inc (NASDAQ:PTLA) – Stock analysts at Oppenheimer cut their FY2022 earnings per share (EPS) estimates for shares of Portola Pharmaceuticals in a report released on Wednesday, November 6th. Oppenheimer analyst J. Olson now expects that the biopharmaceutical company will post earnings per share of $0.50 for the year, down from their prior forecast of $0.51.
A number of other equities analysts have also issued reports on PTLA. Zacks Investment Research upgraded Portola Pharmaceuticals from a “hold” rating to a “buy” rating and set a $30.00 target price for the company in a research note on Wednesday, October 9th. BidaskClub upgraded Portola Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, October 24th. Cowen restated a “buy” rating and issued a $45.00 target price on shares of Portola Pharmaceuticals in a research note on Tuesday. William Blair restated a “buy” rating on shares of Portola Pharmaceuticals in a research note on Friday, August 9th. Finally, ValuEngine lowered Portola Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Monday, October 21st. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $38.75.
PTLA stock traded up $0.07 during midday trading on Friday, reaching $28.45. The stock had a trading volume of 926,800 shares, compared to its average volume of 1,150,857. The stock has a market cap of $2.08 billion, a PE ratio of -5.68 and a beta of 2.08. The company has a debt-to-equity ratio of 453.47, a quick ratio of 3.61 and a current ratio of 3.63. The firm has a fifty day simple moving average of $28.18 and a two-hundred day simple moving average of $28.74. Portola Pharmaceuticals has a 52-week low of $14.81 and a 52-week high of $37.95.
Portola Pharmaceuticals (NASDAQ:PTLA) last posted its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.82) by $0.14. The firm had revenue of $36.80 million during the quarter, compared to analysts’ expectations of $34.64 million. Portola Pharmaceuticals had a negative return on equity of 529.08% and a negative net margin of 275.13%. The business’s quarterly revenue was up 159.2% on a year-over-year basis. During the same quarter last year, the firm earned ($1.08) EPS.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in PTLA. Campbell & CO Investment Adviser LLC purchased a new position in shares of Portola Pharmaceuticals during the 2nd quarter valued at about $895,000. Fox Run Management L.L.C. purchased a new position in shares of Portola Pharmaceuticals during the 2nd quarter valued at about $220,000. Peregrine Capital Management LLC raised its stake in shares of Portola Pharmaceuticals by 8.7% during the 2nd quarter. Peregrine Capital Management LLC now owns 464,465 shares of the biopharmaceutical company’s stock valued at $12,601,000 after buying an additional 37,157 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. raised its stake in shares of Portola Pharmaceuticals by 45.2% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 18,310 shares of the biopharmaceutical company’s stock valued at $497,000 after buying an additional 5,700 shares during the last quarter. Finally, Fisher Asset Management LLC raised its stake in shares of Portola Pharmaceuticals by 16.6% during the 2nd quarter. Fisher Asset Management LLC now owns 100,722 shares of the biopharmaceutical company’s stock valued at $2,733,000 after buying an additional 14,338 shares during the last quarter.
In related news, Director Hollings Renton sold 5,000 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $30.00, for a total value of $150,000.00. Following the completion of the transaction, the director now owns 18,194 shares in the company, valued at approximately $545,820. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 4.50% of the company’s stock.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.
Featured Story: Stocks at 52 Week High
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.